Medical Information

Valemetostat is an EZH1/EZH2 inhibitor used to treat adult T-cell leukemia/lymphoma. Some groups of people have significantly increased risk of using it, and it is necessary to clarify contraindications or carefully evaluate it.

1、 Severe bone marrow suppression patients

1. Medication risks

Valemetostat can cause thrombocytopenia, neutropenia, and anemia. Patients with severe bone marrow suppression may experience further exacerbation after medication, increasing the risk of bleeding, infection, and anemia.

2. Taboos and Caution

Patients with severe bone marrow suppression should avoid using it or use it with caution after careful evaluation by a doctor. Regular monitoring of blood routine is required before and during treatment.

3. Infection and bleeding prevention

Individuals with severe neutropenia should prevent infection and avoid crowded places; Patients with severe thrombocytopenia should avoid bumping and vigorous activity, and pay attention to signs of bleeding.

4. Dose adjustment

If severe bone marrow suppression occurs, doctors may suspend medication, reduce dosage, or permanently stop medication, and patients cannot adjust on their own.

2、 Pregnant women

1. Fetal risk

Based on its mechanism of action, Valemetostat may cause harm to the fetus. Animal studies suggest that it has embryonic fetal toxicity, and its use during pregnancy may lead to miscarriage or fetal malformation.

2. Taboo principle

Pregnant women are prohibited from using Valemetostat. Women of childbearing age should confirm their pregnancy status before taking medication, and effective contraceptive measures should be taken during treatment and for a period of time after the last dose.

3. Management of unintended pregnancy

If pregnancy or suspected pregnancy occurs during treatment, the doctor should be informed immediately to assess the risk to the fetus and adjust the treatment plan.

3、 Breastfeeding patients

1. Breastfeeding risk

It is not yet clear whether Valemetostat is secreted into human milk. Due to the potential for serious adverse reactions to breastfed infants, lactating women should avoid using it.

2. Stop breastfeeding

If Valemetostat must be used, breastfeeding should be stopped during the treatment period and for a period of time after the last dose, and the specific duration should follow the doctor's advice.

3. Alternative feeding

During the discontinuation of medication, alternative feeding methods such as formula milk can be chosen to ensure the nutritional needs of infants.

4、 Other cautious groups

1. Liver dysfunction

The medication data for patients with moderate to severe liver function impairment is limited, and caution should be exercised and monitoring should be strengthened.

2. Renal insufficiency

Patients with severe renal impairment need to assess the risk and adjust the dosage if necessary.

3. Male of childbearing age

The impact on male fertility is not yet clear, and those planning to have children should discuss the risks with their doctors.

4. Combination medication

Avoid co administration with potent CYP3A inhibitors or inducers to avoid affecting drug concentration.